Phase Ib study of lumretuzumab plus cetuximab or erlotinib in solid tumor patients and evaluation of HER3 and heregulin as potential biomarkers of clinical activity

1. Meulendijks, D.
2. Jacob, W.
3. Voest, E.E.
4. Mau-Sorensen, M.
5. Martinez-Garcia, M.
6. Taus, A.
7. Fleitas, T.
8. Cervantes, A.
9. Lolkema, M.P.
10. Langenberg, M.H.G.
11. De Jonge, M.J.
12. Sleijfer, S.
13. Han, J.-Y.
14. Calles, A.
15. Felip, E.
16. Kim, S.-W.
17. Schellens, J.H.M.
18. Wilson, S.
19. Thomas, M.
20. Ceppi, M.
21. Meneses-Lorente, G.
22. James, I.
23. Vega-Harring, S.
24. Dua, R.
25. Nguyen, M.
26. Steiner, L.
27. Adessi, C.
28. Michielin, F.
29. Bossenmaier, B.
30. Weisser, M.
31. Lassen, U.N.
32. Show all authors +

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1158/1078-0432.CCR-17-0812 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

• 

Data source: Scopus